The Center for Advanced Cell Technologies ReoCell was represented at the scientific and practical conference ASIR 2026 “Current Challenges in the Treatment of Complications of Traumatic Injuries”, held on March 26–27 in Lviv.
More details about the conference
During the event, leading specialists of the ReoCell team presented advanced approaches to the application of cell-based technologies in traumatology and orthopedics, as well as clinical outcomes of patient treatment using mesenchymal stem cells (MSCs).
In particular, a scientific presentation was delivered by the Medical Director of ReoCell Clinic, orthopedic surgeon and traumatologist, PhD Dmytro Horban, titled: “Orthobiologics in Modern Surgical Practice”
One of the key messages of the presentation highlighted that degenerative tissue changes are directly associated with chronic inflammation, which progresses with age and leads to a decline in function and quality of life.
Therefore, regenerative medicine is increasingly considered a promising therapeutic approach for degenerative joint disorders.
The presentation emphasized that MSCs represent a key tool in regenerative medicine due to their ability to:
Importantly, the primary therapeutic effect of MSCs is mediated not only through differentiation but predominantly via paracrine signaling and regulation of inflammation.
The presentation also outlined the global development of cell-based therapies:
These data reflect the growing scientific and clinical interest in regenerative medicine and its integration into modern medical practice.
The presentation included clinical outcomes of patients treated at ReoCell Clinic using MSC-based therapy, demonstrating positive dynamics across key clinical parameters.
At 6 months post-treatment:
Assessment using the WOMAC scale demonstrated significant functional improvement:
Additional findings included:
These findings indicate restoration of joint biomechanics.
Clinical outcomes for long bone nonunions included:
These results demonstrate the potential of MSC therapy in complex clinical scenarios.
The obtained results suggest that MSC therapy, as part of a multimodal treatment approach, may:
Participation in ASIR 2026 confirms ReoCell’s active integration into the scientific and medical community of Ukraine.
The presented data demonstrate that cell-based technologies are becoming an important tool in the management of orthopedic conditions, offering new opportunities for disease control and preservation of function.
ReoCell is a cell technology center in Kyiv. We cover the full regenerative medicine cycle: we manufacture cell-based products in our biotechnology laboratory and use them to treat patients at ReoCell Clinic. Our biobank and clinic hold a license from the Ministry of Health of […]
Mesenchymal stem cells are the foundation of cell therapy at ReoCell. The center manages the entire process, from cell-based product manufacturing in its biotechnology laboratory to their clinical application by ReoCell Clinic physicians in traumatology, neurology, endocrinology, vascular surgery, dermatology, and other medical specialties.
Stroke is still often associated with people over 60-70. In Ukraine, however, it is now being diagnosed in patients as young as 30, whereas the disease was previously rarely discussed in connection with young age. At the same time, advances in diagnostic methods make it […]
Closing this window, you agree that you have read the information below.
SELF-MEDICATION CAN BE HARMFUL TO YOUR HEALTH!